Amgen at Morgan Stanley Conference: Strategic Growth and Challenges

Amgen reported strong Q2 financial results, with revenue up 9% and non-GAAP EPS increasing 21%, driven by robust performance across key growth products and significant biosimilar sales. The company is making substantial U.S. manufacturing investments, including a $2.3 billion CapEx guide for the year, and advancing a promising late-stage pipeline with assets like Maridebart Cafraglutide and Olpasiran. While anticipating some revenue erosion in the second half due to denosumab biosimilar competition, Amgen remains focused on innovation, strategic business development, and returning capital to shareholders, aiming to restore its pre-Horizon acquisition capital structure by year-end.

Analysis

Amgen presented a strong operational and financial update, highlighting robust Q2 performance with a 9% year-over-year revenue increase and a 21% jump in non-GAAP EPS, fueled by 13% volume growth. This strength is broad-based, with fifteen products achieving double-digit growth and key franchises like Repatha, Evenity, Tezspire, and Blincyto delivering growth rates between 30% and 46%. The company's biosimilars portfolio is a significant contributor, growing 37% in H1 to nearly $1.4 billion. A key headwind is the anticipated revenue erosion from denosumab biosimilars in the second half of the year, though management appears prepared for this impact. Strategically, Amgen is making substantial capital investments in U.S. manufacturing, with over $2.9 billion committed to expansions in North Carolina and Ohio, supported by a $2.3 billion CapEx guide for the current year. The late-stage pipeline shows significant promise, with Maridebart Cafraglutide advancing in four Phase III obesity-related trials, Olpasiran progressing in Phase III for cardiovascular risk, and Tarlatamab demonstrating strong early commercial traction with 65% quarter-over-quarter growth. Financially, the company is on track to restore its pre-Horizon acquisition capital structure by year-end, which enhances its flexibility for future business development and capital return.

Key Decisions for Investors

• Investors should weigh the strong underlying performance of the core growth drivers and biosimilars against the anticipated, and seemingly priced-in, revenue erosion from the denosumab loss of exclusivity in the second half of the year.
• Monitor key pipeline catalysts, particularly the upcoming Q4 Phase II data for the obesity drug Maridebart Cafraglutide and the commercial ramp-up of Tarlatamab, which represent significant long-term value creation opportunities.
• Given that deleveraging from the Horizon acquisition is on schedule to complete by year-end, anticipate increased strategic flexibility for bolt-on acquisitions and shareholder returns, which could serve as a positive catalyst.
• Watch for management commentary on the competitive dynamics for Rocatinlimab, as the company is currently evaluating the complete data set before determining a path forward in a crowded market.